Colorectal Cancer – Vitamin C in RAS mutated patients
The Rational for Vitamin C in Colorectal Cancer The use of vitamin C in cancer treatment can be traced to more than 40 years ago.
Small Cell Lung Cancer – Seplulimab Prolongs Life
Background In this randomized clinical trial that included 585 patients with extensive-stage Small Cell Lung Cancer, SCLC, who had not previously received systemic therapy, Seplulimab
Renal Cell Cancer – Triplet Therapy Improves Outcomes
Background A significant period until disease progression was seen in patients with metastatic renal cell cancer (RCC) receiving the triplet combination of Cometriq plus Yervoy
Bladder Cancer – Padcev Plus Keytruda in 1st Line
BACKGROUND Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic bladder cancer. However, toxicity is substantial, responses are rarely durable, and
Breast Cancer – Lurbinectadin in BRCA patients
Background Lurbinectedin, a selective inhibitor of oncogenic transcription, has shown preclinical antitumor activity against homologous recombination repair-deficient (HRD) models and preliminary clinical activity in BRCA1/2
Glioblastoma, GBM – A New & Novel Option for Patients
Background – Glioblastoma and CV-01 Glioblastoma is a diffuse, infiltrative disease with tumor cells invading far beyond the borders of the visible tumor. The diffuse
Breast Cancer – Benefits of Trodelvy in HR+/HER2-
Background The antibody-drug conjugate Trodelvy offers statistically and clinically significant benefits for patients with heavily pretreated HR+/HER2- breast cancer, according to results of the TROPiCS-02
Colorectal Cancer – New 1st for Left-Sided RAS-WT
Overview Colorectal cancer is one of the most common types of malignant tumors in humans. According to statistics, the risk of developing this tumor in
Cholangiocarcinoma – Imfinzi plus Gemzar and Cisplatin
Background Biliary tract cancer is a group of malignancies that includes intrahepatic and extrahepatic cholangiocarcinoma, gallbladder cancer, and ampulla of Vater cancer. It is typically
Endometrial Cancer – Vistusertib Plus Arimidex in Patients With HR+
Importance Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors, (AIs). The uncontrolled PI3K-AKT-mTOR pathway observed in this type of cancer drives hormonal resistance.
Lung Cancer – Another new drug for EGFR: Ameile
Background Epidermal Growth Factor Receptor, EGFR, mutations are one of the most common driver mutations in Non–Small-Cell Lung Cancer, NSCLC. Tagrisso, a third-generation EGFR tyrosine
